Merck Sharp + Dohme Corp.

Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Scheeing Corporation

Purakkattle J Biju

Younong Yu

Arthur G Taveras

Jianhua Chao

John J Baldwin

Kevin D McCormick

Robert G Aslanian

Hongjun Zhang

Tesfaye Biftu

Hubert B Josien

Xianhai Huang

Ge Li

William K Hagmann

Ravi P Nargund

Bin Hu

Christopher W Boyce

Junying Zheng

Anandan Palani

Michael P Dwyer

Qun Dang

Dong Xiao

Michael Berlin

Phieng Siliphaivanh

Cheng Zhu

Bing Li

Manuel De Lera Ruiz

Zhengxia Chen

Wei Zhou

Jianping Chao

Anilkumar G Nair

Joseph A Kozlowski

Yongxin Han

David James Witter

Stephane L Bogen

Kun Liu

Steven L Colletti

David L Sloman

Shuwen He

Joey Lee Methot

Liangqin Guo

Daniel M Solomon

Joshua Close

Robert D Mazzola, Jr

Derun Li

Linus S Lin

Nunzio Sciammetta

Abdelghani Achab

Yongqi Deng

Ashwin Umesh Rao

Xavier Fradera

Yeon-Hee Lim

Christopher W Plummer

Qinglin Pu

Qin Jiang

Min K Park

Hua Zhou

Neng-Yang Shih

Brian Alexander McKittrick

Amjad Ali

Barbara A Pio

Wensheng Yu

Jason D Brubaker

Ying Huang

Feroze Ujjainwalla

Michael Man-Chu Lo

Zhicai Wu

Pauline C Ting

Michelle R Machacek

Guoqing Li

Zhi-Cai Shi

Ryan D Otte

Bowei Wang

Joon Jung

Rongze Kuang

Harry R Chobanian

Pietro Mangiaracina

Craig R Gibeau

Xiao Chen

Michael Hale Reutershan

Timothy J Henderson

Matthew Lloyd Childers

John W Butcher

John P Caldwell

Catherine M White

De-Yi Yang

Lei Chen

Christian Fischer

Tao Yu

Tony Priestley

Peter H Fuller

Jayaram R Tagat

Timothy A Blizzard

John W Lampe

Tanweer A Khan

Meredeth Ann McGowan

Yonglian Zhang

Haiqun Tang

Heping Wu

Jessica Frie

Chia-Yu Huang

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Compounds as indoleamine 2,3-dioxygenase inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. 

Tricyclic compounds as inhibitors of mutant IDH enzymes

The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. 

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R, R, R, R, R, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: 

C20-C21 substituted glucocorticoid receptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

ALPHA2C adrenoreceptor agonists

Growing community of inventors

Scotch Plains, NJ, United States of America

Purakkattle J Biju